Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ABBOTT LABORATORIES Director's Dealing 2021

Feb 24, 2021

29777_dirs_2021-02-23_4e592d3a-edce-43c1-9c56-3a45b69a8ad5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2021-02-19

Reporting Person: Ford Robert B (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-02-19 Common shares without par value A 70058 Acquired 179683 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-02-19 Option (right to buy) $124.04 A 359090 Acquired 2031-02-18 Common Shares (359090) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common shares without par value 135243 Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Held in the Ford Family Trust DTD June 2, 2014. The reporting person is co-trustee of the trust.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 119,696 on February 19, 2022, 119,697 on February 19, 2023, and 119,697 on February 19, 2024.